Receptor tyrosine kinases in disease
- Submission status
- Closed
- Submission deadline
Receptor tyrosine kinases (RTKs) are vital cellular signaling molecules. However, because of their ability to rapidly amplify extracellular signals, RTKs and their associated signaling pathways are often implicated in disease. Although many RTKs are targetable with tyrosine kinase inhibitors, patients almost inevitably develop resistance. Understanding the roles of these signaling pathways in disease can help us understand how to best target them and identify mechanisms of resistance.
This collection is dedicated to the role of RTKs in disease, including understanding how these signaling pathways promote pathogenesis, identifying novel mutations, improving treatment methods, and examining downstream signaling pathways.
Editors
-
Ira Daar ,
Ira Daar
National Cancer Institute, USA
-
Paul Dent
Virginia Commonwealth University, USA
-
Michael Simons
MD Yale University School of Medicine, USA
Dr. Daar investigated the molecular defects underlying common glycolytic enzyme deficiencies, and performed some of the earliest studies on nonsense- mediated mRNA decay. His postdoctoral training focused on signal transduction events and cell cycle control points influenced by oncogene function. Currently, his laboratory focuses on Eph/ephrin signaling system and its mechanistic role in cell-cell adhesion and cell movement during development. Dr. Daar has been an Editorial Board Member for Scientific Reports since April 2015.
Dr. Dent attended the University of Newcastle upon Tyne graduating with a B.Sc. (Hons, 1st) in Biochemistry in 1988. Since 1996 Dr. Dent has worked at Virginia Commonwealth University, in Richmond Virginia, initially in Radiation Oncology and subsequently in Biochemistry and Molecular Biology. Dr. Dent has expertise in the areas of signal transduction (receptors and pathways; inhibitors of protein kinases), apoptosis, autophagy, ER stress signaling and with radiobiology and tumor cell radiosensitization. He has published extensively in developing multiple novel drug combinations, with over ten concepts translated from the bench to the bedside in solid tumors. Dr. Dent has been an Editorial Board Member for Scientific Reports since July 2019.
Professor. Simons is a Professor of Medicine at Yale University School of Medicine. Professor Simons is vascular molecular biologist and cardiologist with a long track record of basic, translational and clinical investigations. Professor Simons has been an Editorial Board Member for Scientific Reports since April 2015.
